Dosing & Uses
AdultPediatric
See pediatric dosing and uses
Neuroblastoma
Pending FDA approval for radioimmunotherapy in pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma
Next:
Pharmacology
Mechanism of Action
Radiolabeled monoclonal antibody conjugate
Upon intracerebroventricular administration, omburtamab binds to B7-H3 expressed on certain tumor cells; upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells
B7-H3 is overexpressed on certain tumor cell types and on various immune cells, but is minimally expressed by normal human tissues; B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
